← All trials
NCT05657444
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 15, 2023
- Primary completion
- Feb 15, 2025
- Completion date
- Feb 15, 2025
- First posted
- Dec 20, 2022
- Last posted
- Dec 20, 2022
- Enrollment
- 372
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- People's Liberation Army of ChinaLead sponsor
- People's Liberation Army of ChinaReponsible party - principal investigator
- Cerebrovascular Disease Collaboration & Innovation Alliance of LiaoningCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.